SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) 52 Week High Streak Hits Second Straight Session
- October 1, 2026
- Posted by: Kunal Singla
- Category: News
SYMBIOTEC PHARMALAB LTD 52 Week High Streak has now extended to a second straight session, with the stock setting a fresh 52-week high again at Rs 1,306.40. Across the streak, the share price has moved up 9.77%, and the latest traded price was Rs 1,287.80. According to latest Univest figures, the pattern is confirmed by price action, but it does not by itself establish a company-specific catalyst for the repeated highs.
At 15 October 2026 at 9:52 AM IST, the stock was trading above its previous close of Rs 1,251.60 after opening at Rs 1,257.65 and touching a low of Rs 1,247.60. The market capitalisation stood at Rs 7,538.21 crore. For a reader following the SYMBIOTEC PHARMALAB LTD 52 Week High Streak, the key difference from a single-day breakout is the repeated confirmation of a new yearly high across more than one session, while the reason for that pattern remains unconfirmed by the price data alone.
SYMBIOTEC PHARMALAB LTD 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,287.8 |
| Previous Close | Rs 1,251.6 |
| Today's Move | +Rs 36.2 (+2.89%) |
| Open | Rs 1,257.65 |
| High | Rs 1,306.4 |
| Low | Rs 1,247.6 |
| Market Capitalisation | Rs 7,538.21 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) traded at Rs 1,287.8 versus the previous close of Rs 1,251.6, a rise of 2.89%. The stock opened at Rs 1,257.65, reached a high of Rs 1,306.4 and touched a low of Rs 1,247.6.
SYMBIOTEC PHARMALAB LTD Share Price Today shows the stock trading at Rs 1,287.80, which is Rs 36.20 or 2.89% above the previous close of Rs 1,251.60. The intraday range has been tight enough to keep the latest traded price well above the opening level of Rs 1,257.65 and far below the day high of Rs 1,306.40, which is also the fresh 52-week high for the SYMBIOTEC PHARMALAB LTD 52 Week High Streak.
The day low stood at Rs 1,247.60, so the current quote was trading above the lower end of the range and not at the peak of the move. Market capitalisation was Rs 7,538.21 crore, placing the company in the same valuation conversation as several listed healthcare peers in the pharmaceuticals and drugs space. For the SYMBIOTEC PHARMALAB LTD 52 Week High Streak, the important point is that the stock is not only trading near its yearly peak but has now repeated that pattern across consecutive sessions.
What the Repeated 52-Week Highs Show
The SYMBIOTEC PHARMALAB LTD 52 Week High Streak now covers two consecutive sessions, and that is the clearest fact the market data establishes. The stock first moved to a fresh 52-week high on 14 October 2026 and then extended that high again on the next trading session, lifting the latest peak to Rs 1,306.40. Across those two sessions, the cumulative move was 9.77%.
What the repeated highs show is a price pattern, not a confirmed reason. The data does not name a company-specific development that explains why SYMBIOTEC PHARMALAB LTD kept registering a new one-year high. For readers, the value of the SYMBIOTEC PHARMALAB LTD 52 Week High Streak lies in the confirmation that the move was not a one-off print. It was a back-to-back extension of the yearly high, and the latest high is the number to watch against the next traded price.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 7,538.21 crore |
| P/E Ratio | 73.18x |
| P/B Ratio | 5.36x |
| ROE | 11.22% |
| ROCE | 12.41% |
| EPS | Rs 17.1 |
| Book Value Per Share | Rs 233.38 |
| Dividend Yield | 0% |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) fundamental metrics show P/E 73.18x, P/B 5.36x, ROE 11.22%, ROCE 12.41%. These ratios show where the company stands today and are not a call to buy or sell.
SYMBIOTEC PHARMALAB LTD has a market capitalisation of Rs 7,538.21 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 73.18x, P/B at 5.36x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 17.1, book value per share of Rs 233.38, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.34x, median ROE of 11.69%, median ROCE of 13.61%. Together they describe the fundamental backdrop without implying a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 73.18x |
| Benchmark Median P/E | 31.34x |
| Benchmark Average P/E | 46.76x |
| Benchmark P/E Range | 3.13x to 654.72x |
| Company P/B Ratio | 5.36x |
| Benchmark Median P/B | 2.83x |
| Company ROE | 11.22% |
| Benchmark Median ROE | 11.69% |
| Company ROCE | 12.41% |
| Benchmark Median ROCE | 13.61% |
| Company Market Capitalisation | Rs 7,538.21 crore |
| Benchmark Median Market Cap | Rs 808.34 crore |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 73.18x, which is above the benchmark median of 31.34x, a difference of +133.5%. A P/E difference of this kind is a reference point rather than a recommendation.
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROE of 11.22%, which is below the benchmark median of 11.69%, a difference of -4.02%. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a ROCE of 12.41%, which is below the benchmark median of 13.61%, a difference of -8.82%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Bliss GVS Pharma Ltd. | BLISSGVS | 7,136.37 | 51.62 | 5.7 | 12.11 | 17.4 |
| Aarti Pharmalabs Ltd. | AARTIPHARM | 8,019.72 | 36.86 | 3.59 | 8.5 | 10.77 |
| Supriya Lifescience Ltd. | SUPRIYA | 7,040.64 | 35.49 | 5.76 | 19.06 | 25.3 |
| Sanofi India Ltd. | SANOFI | 6,819.94 | 21.22 | 8.32 | 44.5 | 55.46 |
| Sanofi Consumer Healthcare India Ltd. | SANOFICONR | 8,339.73 | 31.35 | 23.97 | 73.2 | 98.11 |
SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a P/E ratio of 73.18x compared with the displayed peer median of 35.49x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.22% compares with a peer median of 19.06% across the companies shown in the table. ROCE stood at 12.41% versus the displayed peer median of 25.3%, providing a capital-efficiency comparison. SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) has a market capitalisation of Rs 7,538.21 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching SYMBIOTEC PHARMALAB LTD
- The SYMBIOTEC PHARMALAB LTD 52 Week High Streak has now stretched to a second straight session.
- The latest fresh 52-week high stood at Rs 1,306.40.
- The cumulative move across the streak was 9.77%.
- The latest traded price was Rs 1,287.80, above the previous close of Rs 1,251.60.
- The stock’s P/E ratio of 73.18 is well above the industry median of 31.34.
About SYMBIOTEC PHARMALAB LTD
SYMBIOTEC PHARMALAB LTD operates in the Pharmaceuticals & Drugs industry within Healthcare. For a reader following the SYMBIOTEC PHARMALAB LTD 52 Week High Streak, the useful business context is that the company sits in a sector where valuation, earnings quality and return ratios are commonly compared across a wide listed universe. The current streak therefore has to be read alongside the company’s earnings base, book value and sector benchmarks rather than as a standalone price event.
The latest market capitalisation of Rs 7,538.21 crore and the current valuation metrics make the stock relevant for investors who track yearly highs in healthcare names. The SYMBIOTEC PHARMALAB LTD 52 Week High Streak is most meaningful when viewed as a price pattern unfolding against those operating and valuation markers.
Track SYMBIOTEC PHARMALAB LTD on Univest
Track SYMBIOTEC PHARMALAB LTD on Univest to follow the latest traded price, yearly-high updates, valuation ratios and company snapshots in one place. For readers monitoring the SYMBIOTEC PHARMALAB LTD 52 Week High Streak, the page helps keep the price move, sector comparison and peer context together as new market data arrives.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
What does the SYMBIOTEC PHARMALAB LTD 52 Week High Streak mean?
Ans. It means SYMBIOTEC PHARMALAB LTD has set a fresh 52-week high on more than one consecutive trading session. In this case, the streak has reached a second straight session, which points to a repeated yearly-high pattern rather than a one-day breakout.
How many sessions has SYMBIOTEC PHARMALAB LTD made a fresh 52-week high?
Ans. The current SYMBIOTEC PHARMALAB LTD 52 Week High Streak spans two consecutive sessions. The first fresh high came on 14 October 2026, and the next session extended that high again.
What is the cumulative move across the SYMBIOTEC PHARMALAB LTD 52 Week High Streak?
Ans. The cumulative move across the SYMBIOTEC PHARMALAB LTD 52 Week High Streak is 9.77%. That is the full streak gain, not just the latest day’s move.
What is the latest 52-week high for SYMBIOTEC PHARMALAB LTD?
Ans. The latest fresh 52-week high for SYMBIOTEC PHARMALAB LTD is Rs 1,306.40. That is the peak touched during the current streak. The stock moved 2.89% so far today.
How does the current price compare with the previous close?
Ans. The latest traded price was Rs 1,287.80 versus a previous close of Rs 1,251.60. That means the stock was trading Rs 36.20 higher, or 2.89% above the prior close.
Is there a confirmed company-specific catalyst for the repeated highs?
Ans. No confirmed company-specific catalyst is established by the price data alone. The SYMBIOTEC PHARMALAB LTD 52 Week High Streak confirms the repeated price pattern, but not the reason behind it.
How is SYMBIOTEC PHARMALAB LTD valued versus its industry?
Ans. The stock trades at a P/E ratio of 73.18 and a P/B ratio of 5.36, both above the industry medians of 31.34 and 2.83. That places the SYMBIOTEC PHARMALAB LTD 52 Week High Streak at a premium to the broader industry benchmark.
What should investors watch next in SYMBIOTEC PHARMALAB LTD?
Ans. Investors can watch whether the stock continues to hold near the latest high of Rs 1,306.40 and whether subsequent traded prices keep extending the streak. They can also track valuation ratios, earnings ratios and sector comparison.
Track SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) Share Price on Univest
Use SYMBIOTEC PHARMALAB LTD (SYMBIOTEC) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
